Eric L. Smith, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 11 | 2023 | 1271 | 2.860 |
Why?
|
| Multiple Myeloma | 8 | 2023 | 5185 | 1.330 |
Why?
|
| B-Cell Maturation Antigen | 4 | 2022 | 140 | 1.130 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2022 | 1222 | 0.900 |
Why?
|
| Antigens, CD19 | 2 | 2022 | 380 | 0.700 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2023 | 2540 | 0.660 |
Why?
|
| Treatment Failure | 1 | 2020 | 2617 | 0.490 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 1377 | 0.440 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2022 | 1052 | 0.430 |
Why?
|
| T-Lymphocytes | 4 | 2022 | 10179 | 0.290 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 4665 | 0.270 |
Why?
|
| Neoplasms | 2 | 2023 | 21675 | 0.220 |
Why?
|
| Single-Chain Antibodies | 1 | 2019 | 108 | 0.160 |
Why?
|
| Antibody Specificity | 1 | 2019 | 1095 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 9239 | 0.120 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 1876 | 0.120 |
Why?
|
| Receptors, Antigen | 1 | 2013 | 53 | 0.120 |
Why?
|
| Mice, SCID | 1 | 2019 | 2718 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2022 | 2131 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3547 | 0.100 |
Why?
|
| Humans | 12 | 2023 | 743811 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 3772 | 0.080 |
Why?
|
| Recurrence | 1 | 2020 | 8337 | 0.080 |
Why?
|
| Mice | 3 | 2022 | 81154 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2022 | 16674 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 7908 | 0.070 |
Why?
|
| Gene Expression | 1 | 2019 | 7793 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3706 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2022 | 7880 | 0.060 |
Why?
|
| Animals | 4 | 2022 | 168660 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2019 | 13028 | 0.060 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 1832 | 0.050 |
Why?
|
| Aged | 2 | 2022 | 163178 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2017 | 527 | 0.030 |
Why?
|
| Female | 2 | 2022 | 380020 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2019 | 63042 | 0.030 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 222 | 0.030 |
Why?
|
| Middle Aged | 1 | 2022 | 213241 | 0.020 |
Why?
|
| Male | 1 | 2022 | 349776 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2013 | 3524 | 0.010 |
Why?
|